Identification and treatment of T2-low asthma in the era of biologics

Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ERJ open research Ročník 7; číslo 2; s. 309
Hlavní autoři: Kyriakopoulos, Chris, Gogali, Athena, Bartziokas, Konstantinos, Kostikas, Konstantinos
Médium: Journal Article
Jazyk:angličtina
Vydáno: England European Respiratory Society 01.04.2021
Témata:
Reviews
ISSN:2312-0541, 2312-0541
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
AbstractList Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma. Th2-low endotype of asthma occurs in 50% of asthma patients. Novel targeted treatment with biologic agents is not currently approved. Nevertheless, other therapeutic options exist. Licensed drugs, novel molecules and biologics agents are under development. https://bit.ly/3bW7G0Q
Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma. Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation. This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
Author Bartziokas, Konstantinos
Kostikas, Konstantinos
Gogali, Athena
Kyriakopoulos, Chris
AuthorAffiliation Respiratory Medicine Dept, University of Ioannina School of Medicine, Ioannina, Greece
AuthorAffiliation_xml – name: Respiratory Medicine Dept, University of Ioannina School of Medicine, Ioannina, Greece
Author_xml – sequence: 1
  givenname: Chris
  orcidid: 0000-0001-8806-2561
  surname: Kyriakopoulos
  fullname: Kyriakopoulos, Chris
– sequence: 2
  givenname: Athena
  surname: Gogali
  fullname: Gogali, Athena
– sequence: 3
  givenname: Konstantinos
  orcidid: 0000-0002-9657-3705
  surname: Bartziokas
  fullname: Bartziokas, Konstantinos
– sequence: 4
  givenname: Konstantinos
  orcidid: 0000-0003-0774-3942
  surname: Kostikas
  fullname: Kostikas, Konstantinos
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34109244$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv3CAUhVGVqnn-gkqVl9045QI2sKlURXmMFKmbZI0wjxki26TAtOq_L57JVEkXXYHOvfc7F84pOprj7BD6CPgSQNAvhALBHYNLjCmWLcEEv0Mni9ou8tGr-zG6yPkJYwwdEazvP6BjygBLwtgJul5ZN5fgg9ElxLnRs21KcrpMVW6ibx5IO8Zfjc5lM-kmzE3ZuMYlvdSGEMe4Diafo_dej9ldvJxn6PHm-uHqrr3_fru6-nbfGsahtN6CprYX3DsgjOCeeM4H1g0DSBC-Gzo7ON07hwnz1lNpjCVQNW69kRzoGVrtuTbqJ_WcwqTTbxV1UDshprXSqQQzOsWt9vWjuKC2Y8JY0UsgxktKnZZ08JX1dc963g6Ts6a-N-nxDfRtZQ4btY4_lQABXOIK-PwCSPHH1uWippCNG0c9u7jNinRUiroBdLX102uvvyaHHGqD3DeYFHNOzisTyi6Rah1GBVgtsatD7GoXu1pir7P0n9kD_n9TfwBoU66N
CitedBy_id crossref_primary_10_1186_s12929_025_01142_w
crossref_primary_10_3390_genes14091824
crossref_primary_10_1016_j_anai_2022_04_020
crossref_primary_10_1080_14656566_2024_2389258
crossref_primary_10_1016_j_jaip_2023_05_028
crossref_primary_10_1016_j_rmed_2024_107532
crossref_primary_10_7717_peerj_18421
crossref_primary_10_1016_j_freeradbiomed_2021_10_021
crossref_primary_10_3904_kjim_2023_299
crossref_primary_10_1016_j_biopha_2023_114218
crossref_primary_10_1016_j_jacig_2025_100419
crossref_primary_10_1097_CM9_0000000000002456
crossref_primary_10_1111_cea_14149
crossref_primary_10_2147_JAA_S378505
crossref_primary_10_1111_all_16309
crossref_primary_10_1183_13993003_01397_2023
crossref_primary_10_2500_aap_2022_43_220047
crossref_primary_10_3389_fimmu_2023_1207641
crossref_primary_10_1002_eji_202250106
crossref_primary_10_1007_s00408_022_00583_6
crossref_primary_10_3390_jpm12040593
crossref_primary_10_3390_biomedicines9101497
crossref_primary_10_3390_ijms26157629
crossref_primary_10_2147_JAA_S342391
crossref_primary_10_3390_vaccines13050459
crossref_primary_10_1007_s12016_025_09045_2
crossref_primary_10_1183_23120541_01109_2024
crossref_primary_10_1164_rccm_202210_2005OC
crossref_primary_10_3390_biom13071118
crossref_primary_10_1146_annurev_pharmtox_051623_091038
crossref_primary_10_1016_j_rmed_2023_107327
crossref_primary_10_3389_fimmu_2024_1488570
crossref_primary_10_1183_20734735_0267_2022
crossref_primary_10_1016_j_jaip_2025_04_040
crossref_primary_10_1111_all_15390
crossref_primary_10_3389_fphar_2025_1631321
crossref_primary_10_3390_biomedicines11092424
crossref_primary_10_3390_cells11142238
crossref_primary_10_1183_13993003_00700_2023
crossref_primary_10_3390_antiox13111333
crossref_primary_10_1177_03000605241297532
crossref_primary_10_1016_j_resinv_2023_07_003
crossref_primary_10_1016_j_phrs_2023_106658
crossref_primary_10_3390_jpm12010010
crossref_primary_10_1007_s11882_023_01101_1
crossref_primary_10_1007_s10753_024_02159_3
crossref_primary_10_1016_j_pupt_2025_102375
crossref_primary_10_2147_JAA_S466894
crossref_primary_10_1164_rccm_202201_0129OC
crossref_primary_10_1016_j_addr_2023_114858
crossref_primary_10_1016_j_jaip_2025_04_055
crossref_primary_10_3389_fimmu_2022_943554
crossref_primary_10_3390_life14070899
crossref_primary_10_1016_j_pccm_2025_08_003
crossref_primary_10_3390_jpm12030333
crossref_primary_10_1080_14656566_2022_2083955
crossref_primary_10_1111_cea_70084
crossref_primary_10_32895_UMP_MPR_9_1_1
Cites_doi 10.1164/rccm.201602-0419OC
10.1124/jpet.118.249516
10.1165/rcmb.2004-0213OC
10.1097/MCP.0000000000000120
10.1111/j.1398-9995.2009.02122.x
10.1016/j.jaci.2012.08.024
10.1016/S0140-6736(17)31281-3
10.1007/s11882-016-0644-3
10.1056/NEJMc1111248
10.1111/j.1440-1843.2006.00784.x
10.1186/1471-2466-13-33
10.1165/rcmb.2016-0308TR
10.1016/j.ejphar.2005.12.067
10.1164/rccm.200510-1589OC
10.1183/13993003.01074-2018
10.1183/09031936.00117013
10.1016/j.chembiol.2013.09.017
10.1159/000237234
10.1124/jpet.108.144311
10.2147/JAA.S190489
10.1186/s40413-018-0208-1
10.1155/2015/685684
10.1164/ajrccm.154.4.8887608
10.1164/ajrccm.161.1.9802048
10.1111/j.1365-2222.2006.02502.x
10.1183/23120541.00364-2019
10.1177/1753465816632638
10.1183/09031936.00043514
10.1016/j.jaci.2011.12.996
10.1111/j.1365-2222.2012.04014.x
10.1016/j.jaci.2013.10.011
10.1016/S2213-2600(16)30048-0
10.1164/ajrccm.160.5.9806170
10.1002/rcr2.28
10.1007/BF01300701
10.11131/2018/101306
10.1007/s12016-018-8712-1
10.1165/rcmb.2017-0162OC
10.1164/rccm.200809-1512OC
10.1016/j.jaci.2016.02.018
10.1016/S0014-2999(01)01321-8
10.3390/antibiotics5030029
10.1016/j.rmed.2017.12.001
10.1183/09031936.00093913
10.2165/11317130-000000000-00000
10.1016/j.jaci.2013.03.044
10.1164/rccm.200601-072OC
10.1016/j.pupt.2018.11.007
10.1016/S2213-2600(16)30227-2
10.1152/ajplung.00233.2002
10.1183/13993003.01510-2018
10.1186/s12931-016-0436-2
10.4168/aair.2020.12.1.125
10.1007/s10517-016-3458-3
10.1097/MCP.0000000000000226
10.1016/j.rmed.2015.05.003
10.1056/NEJMoa0904006
10.1164/ajrccm.161.2.9903097
10.1371/journal.pone.0100645
10.4049/jimmunol.1301360
10.1016/j.jaci.2009.02.024
10.1378/chest.119.5.1329
10.2500/aap.2016.37.3944
10.1016/j.jaci.2017.03.006
10.1371/journal.pone.0010235
10.1164/rccm.201212-2318OC
10.1186/1471-2431-12-83
10.1111/bph.12187
10.1016/0002-9610(94)90069-8
10.1111/bph.12077
10.1136/gut.33.3.397
10.1056/NEJMra1301758
10.1016/j.freeradbiomed.2013.02.001
10.1007/s00281-016-0556-2
10.1183/13993003.00405-2015
10.1016/j.jaci.2010.03.027
10.1186/1471-2466-13-11
10.1155/2016/6470364
10.1164/rccm.200707-1134OC
10.2147/COPD.S150576
10.1016/j.jaip.2019.04.043
10.1016/j.biopha.2016.06.041
10.1016/j.jaci.2014.07.039
10.1183/13993003.00588-2019
10.1186/s13223-015-0081-1
10.1016/j.rmed.2018.07.006
10.1136/thx.2006.073429
10.1016/j.intimp.2014.08.009
10.1136/thoraxjnl-2014-206067
10.1371/journal.pone.0015781
10.1016/j.ccm.2012.06.008
10.1111/all.13184
10.1136/thx.2006.061358
10.1016/j.anai.2018.08.009
10.1007/s40629-018-0079-6
10.1111/j.1365-2222.2012.03979.x
10.1016/j.chest.2016.03.012
10.1586/eci.10.66
10.1111/bcp.12536
10.1016/j.anai.2016.08.010
10.1186/1465-9921-14-137
10.1164/rccm.201609-1830OC
10.1136/thx.2009.124925
10.1016/j.jaci.2011.04.039
10.1183/09031936.00102014
10.1016/j.jaip.2017.07.010
10.1136/thorax.57.7.590
10.1034/j.1398-9995.2000.00505.x
10.1056/NEJMoa1814917
ContentType Journal Article
Copyright Copyright ©ERS 2021.
Copyright ©ERS 2021 2021
Copyright_xml – notice: Copyright ©ERS 2021.
– notice: Copyright ©ERS 2021 2021
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1183/23120541.00309-2020
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Identification and treatment of T2-low asthma
EISSN 2312-0541
ExternalDocumentID oai_doaj_org_article_7daf183783d548cd86912cf933ea93bf
PMC8181790
34109244
10_1183_23120541_00309_2020
Genre Journal Article
Review
GroupedDBID 53G
5VS
AAYXX
ACEMG
ADBBV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BTFSW
CITATION
EBS
EJD
GROUPED_DOAJ
H13
HYE
IPNFZ
KQ8
M~E
OK1
R0Z
RHI
RIG
RPM
TER
AIPOO
NPM
7X8
5PM
ID FETCH-LOGICAL-c471t-fd1a3d687fe1242062f77b45bb1918f5b5dbea6ee024fdf39ccd21dbe7dfc9713
IEDL.DBID DOA
ISICitedReferencesCount 73
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000684169700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2312-0541
IngestDate Fri Oct 03 12:36:39 EDT 2025
Tue Sep 30 16:50:07 EDT 2025
Sun Aug 24 04:05:22 EDT 2025
Thu Apr 03 07:11:53 EDT 2025
Sat Nov 29 08:19:43 EST 2025
Tue Nov 18 20:25:48 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright ©ERS 2021.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c471t-fd1a3d687fe1242062f77b45bb1918f5b5dbea6ee024fdf39ccd21dbe7dfc9713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-9657-3705
0000-0003-0774-3942
0000-0001-8806-2561
OpenAccessLink https://doaj.org/article/7daf183783d548cd86912cf933ea93bf
PMID 34109244
PQID 2539883715
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_7daf183783d548cd86912cf933ea93bf
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8181790
proquest_miscellaneous_2539883715
pubmed_primary_34109244
crossref_citationtrail_10_1183_23120541_00309_2020
crossref_primary_10_1183_23120541_00309_2020
PublicationCentury 2000
PublicationDate 2021-04-01
PublicationDateYYYYMMDD 2021-04-01
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle ERJ open research
PublicationTitleAlternate ERJ Open Res
PublicationYear 2021
Publisher European Respiratory Society
Publisher_xml – name: European Respiratory Society
References Adeniyi (2024101710515834000_7.2.00309-2020.78) 2012; 7
2024101710515834000_7.2.00309-2020.49
Wang (2024101710515834000_7.2.00309-2020.32) 2015; 12
2024101710515834000_7.2.00309-2020.57
2024101710515834000_7.2.00309-2020.58
2024101710515834000_7.2.00309-2020.59
2024101710515834000_7.2.00309-2020.52
2024101710515834000_7.2.00309-2020.53
Ricciardolo (2024101710515834000_7.2.00309-2020.102) 2016; 48
2024101710515834000_7.2.00309-2020.55
Sifrim (2024101710515834000_7.2.00309-2020.67) 1994; 20
2024101710515834000_7.2.00309-2020.50
2024101710515834000_7.2.00309-2020.51
Ntontsi (2024101710515834000_7.2.00309-2020.37) 2017; 72
Amarasiri (2024101710515834000_7.2.00309-2020.61) 2013; 13
2024101710515834000_7.2.00309-2020.38
Dominguez-Ortega (2024101710515834000_7.2.00309-2020.26) 2016; 16
2024101710515834000_7.2.00309-2020.39
Kuo (2024101710515834000_7.2.00309-2020.12) 2018; 121
van Rijt (2024101710515834000_7.2.00309-2020.3) 2016; 38
2024101710515834000_7.2.00309-2020.45
2024101710515834000_7.2.00309-2020.48
2024101710515834000_7.2.00309-2020.42
Maes (2024101710515834000_7.2.00309-2020.43) 2016; 137
Duong-Quy (2024101710515834000_7.2.00309-2020.11) 2019; 12
Scioscia (2024101710515834000_7.2.00309-2020.15) 2020; 9
2024101710515834000_7.2.00309-2020.44
2024101710515834000_7.2.00309-2020.40
He (2024101710515834000_7.2.00309-2020.109) 2015; 2015
Hernandez (2024101710515834000_7.2.00309-2020.113) 2013; 60
Kuruvilla (2024101710515834000_7.2.00309-2020.2) 2019; 56
Mathur (2024101710515834000_7.2.00309-2020.9) 2016; 117
2024101710515834000_7.2.00309-2020.27
2024101710515834000_7.2.00309-2020.28
2024101710515834000_7.2.00309-2020.29
2024101710515834000_7.2.00309-2020.34
2024101710515834000_7.2.00309-2020.35
2024101710515834000_7.2.00309-2020.30
Yang (2024101710515834000_7.2.00309-2020.21) 2016; 2016
2024101710515834000_7.2.00309-2020.31
Ong (2024101710515834000_7.2.00309-2020.73) 2019; 28
2024101710515834000_7.2.00309-2020.101
2024101710515834000_7.2.00309-2020.33
2024101710515834000_7.2.00309-2020.100
2024101710515834000_7.2.00309-2020.103
2024101710515834000_7.2.00309-2020.105
Lazarus (2024101710515834000_7.2.00309-2020.54) 2019; 380
2024101710515834000_7.2.00309-2020.108
Banno (2024101710515834000_7.2.00309-2020.117) 2018; 5
Lea (2024101710515834000_7.2.00309-2020.119) 2015; 79
O'Byrne (2024101710515834000_7.2.00309-2020.82) 2016; 4
2024101710515834000_7.2.00309-2020.18
2024101710515834000_7.2.00309-2020.23
Hynes (2024101710515834000_7.2.00309-2020.47) 2020; 6
Patel (2024101710515834000_7.2.00309-2020.91) 2018; 13
2024101710515834000_7.2.00309-2020.25
2024101710515834000_7.2.00309-2020.7
2024101710515834000_7.2.00309-2020.5
2024101710515834000_7.2.00309-2020.20
2024101710515834000_7.2.00309-2020.4
2024101710515834000_7.2.00309-2020.22
De Schutter (2024101710515834000_7.2.00309-2020.46) 2012; 12
2024101710515834000_7.2.00309-2020.1
Koziol-White (2024101710515834000_7.2.00309-2020.96) 2016; 193
Pirogov (2024101710515834000_7.2.00309-2020.17) 2016; 161
Miller (2024101710515834000_7.2.00309-2020.106) 2015; 8
Jelić (2024101710515834000_7.2.00309-2020.56) 2016; 5
Haughney (2024101710515834000_7.2.00309-2020.8) 2018; 134
Antoniu (2024101710515834000_7.2.00309-2020.88) 2009; 23
2024101710515834000_7.2.00309-2020.13
2024101710515834000_7.2.00309-2020.121
2024101710515834000_7.2.00309-2020.97
2024101710515834000_7.2.00309-2020.120
2024101710515834000_7.2.00309-2020.98
2024101710515834000_7.2.00309-2020.99
2024101710515834000_7.2.00309-2020.122
2024101710515834000_7.2.00309-2020.92
2024101710515834000_7.2.00309-2020.93
Casale (2024101710515834000_7.2.00309-2020.41) 2017; 139
2024101710515834000_7.2.00309-2020.94
2024101710515834000_7.2.00309-2020.95
2024101710515834000_7.2.00309-2020.90
Schuhmann (2024101710515834000_7.2.00309-2020.75) 2017; 50
Zhang (2024101710515834000_7.2.00309-2020.104) 2016; 83
Zhu (2024101710515834000_7.2.00309-2020.80) 2018; 11
Lucci (2024101710515834000_7.2.00309-2020.107) 2016; 48
2024101710515834000_7.2.00309-2020.89
2024101710515834000_7.2.00309-2020.85
2024101710515834000_7.2.00309-2020.110
2024101710515834000_7.2.00309-2020.86
2024101710515834000_7.2.00309-2020.87
2024101710515834000_7.2.00309-2020.112
2024101710515834000_7.2.00309-2020.111
2024101710515834000_7.2.00309-2020.81
2024101710515834000_7.2.00309-2020.114
2024101710515834000_7.2.00309-2020.83
2024101710515834000_7.2.00309-2020.84
2024101710515834000_7.2.00309-2020.115
2024101710515834000_7.2.00309-2020.118
Chu (2024101710515834000_7.2.00309-2020.116) 2015; 11
Forno (2024101710515834000_7.2.00309-2020.79) 2018; 6
Peters (2024101710515834000_7.2.00309-2020.36) 2016; 4
Ulrik (2024101710515834000_7.2.00309-2020.77) 2016; 22
Ribó (2024101710515834000_7.2.00309-2020.62) 2014; 2
Wardzyńska (2024101710515834000_7.2.00309-2020.14) 2020; 12
Denlinger (2024101710515834000_7.2.00309-2020.24) 2017; 195
2024101710515834000_7.2.00309-2020.76
Shah (2024101710515834000_7.2.00309-2020.6) 2019; 7
2024101710515834000_7.2.00309-2020.70
2024101710515834000_7.2.00309-2020.71
2024101710515834000_7.2.00309-2020.72
Shimoda (2024101710515834000_7.2.00309-2020.19) 2016; 37
Papaioannou (2024101710515834000_7.2.00309-2020.10) 2018; 142
Wen (2024101710515834000_7.2.00309-2020.16) 2010; 5
Laxmanan (2024101710515834000_7.2.00309-2020.74) 2016; 150
2024101710515834000_7.2.00309-2020.68
2024101710515834000_7.2.00309-2020.69
Yoo (2024101710515834000_7.2.00309-2020.124) 2017; 56
2024101710515834000_7.2.00309-2020.63
2024101710515834000_7.2.00309-2020.64
2024101710515834000_7.2.00309-2020.65
2024101710515834000_7.2.00309-2020.66
2024101710515834000_7.2.00309-2020.60
Zhang (2024101710515834000_7.2.00309-2020.123) 2019; 54
References_xml – ident: 2024101710515834000_7.2.00309-2020.85
– volume: 195
  start-page: 302
  year: 2017
  ident: 2024101710515834000_7.2.00309-2020.24
  article-title: Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201602-0419OC
– ident: 2024101710515834000_7.2.00309-2020.93
  doi: 10.1124/jpet.118.249516
– ident: 2024101710515834000_7.2.00309-2020.100
  doi: 10.1165/rcmb.2004-0213OC
– ident: 2024101710515834000_7.2.00309-2020.35
  doi: 10.1097/MCP.0000000000000120
– ident: 2024101710515834000_7.2.00309-2020.92
  doi: 10.1111/j.1398-9995.2009.02122.x
– ident: 2024101710515834000_7.2.00309-2020.25
  doi: 10.1016/j.jaci.2012.08.024
– ident: 2024101710515834000_7.2.00309-2020.70
  doi: 10.1016/S0140-6736(17)31281-3
– volume: 16
  start-page: 63
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.26
  article-title: Biomarkers in occupational asthma
  publication-title: Curr Allergy Asthma Rep
  doi: 10.1007/s11882-016-0644-3
– ident: 2024101710515834000_7.2.00309-2020.60
  doi: 10.1056/NEJMc1111248
– ident: 2024101710515834000_7.2.00309-2020.29
  doi: 10.1111/j.1440-1843.2006.00784.x
– volume: 13
  start-page: 33
  year: 2013
  ident: 2024101710515834000_7.2.00309-2020.61
  article-title: Response of the airways and autonomic nervous system to acid perfusion of the esophagus in patients with asthma: a laboratory study
  publication-title: BMC Pulm Med
  doi: 10.1186/1471-2466-13-33
– volume: 56
  start-page: 700
  year: 2017
  ident: 2024101710515834000_7.2.00309-2020.124
  article-title: Phosphoinositide 3-kinase in asthma: novel roles and therapeutic approaches
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2016-0308TR
– ident: 2024101710515834000_7.2.00309-2020.121
  doi: 10.1016/j.ejphar.2005.12.067
– ident: 2024101710515834000_7.2.00309-2020.52
  doi: 10.1164/rccm.200510-1589OC
– ident: 2024101710515834000_7.2.00309-2020.86
  doi: 10.1183/13993003.01074-2018
– ident: 2024101710515834000_7.2.00309-2020.33
  doi: 10.1183/09031936.00117013
– ident: 2024101710515834000_7.2.00309-2020.94
  doi: 10.1016/j.chembiol.2013.09.017
– ident: 2024101710515834000_7.2.00309-2020.110
  doi: 10.1159/000237234
– ident: 2024101710515834000_7.2.00309-2020.95
  doi: 10.1124/jpet.108.144311
– volume: 12
  start-page: 331
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.11
  article-title: Clinical utility of the exhaled nitric oxide (NO) measurement with portable devices in the management of allergic airway inflammation and asthma
  publication-title: J Asthma Allergy
  doi: 10.2147/JAA.S190489
– ident: 2024101710515834000_7.2.00309-2020.118
– volume: 11
  start-page: 30
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.80
  article-title: Potential new targets for drug development in severe asthma
  publication-title: World Allergy Organ J
  doi: 10.1186/s40413-018-0208-1
– volume: 2015
  start-page: 685684
  year: 2015
  ident: 2024101710515834000_7.2.00309-2020.109
  article-title: Association between polymorphism of interleukin-1 beta and interleukin-1 receptor antagonist gene and asthma risk: a meta-analysis
  publication-title: ScientificWorldJournal
  doi: 10.1155/2015/685684
– ident: 2024101710515834000_7.2.00309-2020.112
  doi: 10.1164/ajrccm.154.4.8887608
– ident: 2024101710515834000_7.2.00309-2020.13
  doi: 10.1164/ajrccm.161.1.9802048
– ident: 2024101710515834000_7.2.00309-2020.40
  doi: 10.1111/j.1365-2222.2006.02502.x
– volume: 6
  start-page: 00364–02019
  year: 2020
  ident: 2024101710515834000_7.2.00309-2020.47
  article-title: The role of interleukin-17 in asthma: a protective response?
  publication-title: ERJ Open Res
  doi: 10.1183/23120541.00364-2019
– ident: 2024101710515834000_7.2.00309-2020.76
  doi: 10.1177/1753465816632638
– ident: 2024101710515834000_7.2.00309-2020.72
  doi: 10.1183/09031936.00043514
– ident: 2024101710515834000_7.2.00309-2020.48
  doi: 10.1016/j.jaci.2011.12.996
– ident: 2024101710515834000_7.2.00309-2020.81
  doi: 10.1111/j.1365-2222.2012.04014.x
– ident: 2024101710515834000_7.2.00309-2020.31
  doi: 10.1016/j.jaci.2013.10.011
– volume: 4
  start-page: 574
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.36
  article-title: Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(16)30048-0
– ident: 2024101710515834000_7.2.00309-2020.39
  doi: 10.1164/ajrccm.160.5.9806170
– volume: 50
  start-page: PA3028
  year: 2017
  ident: 2024101710515834000_7.2.00309-2020.75
  article-title: Reduction of bronchial wall thickness and hyperinflation on quantitative CT after bronchial thermoplasty for severe asthma
  publication-title: Eur Respir J
– volume: 2
  start-page: 1
  year: 2014
  ident: 2024101710515834000_7.2.00309-2020.62
  article-title: Gastroesophageal reflux as a cause of chronic cough, severe asthma, and migratory pulmonary infiltrates
  publication-title: Respirol Case Rep
  doi: 10.1002/rcr2.28
– ident: 2024101710515834000_7.2.00309-2020.63
  doi: 10.1007/BF01300701
– volume: 5
  start-page: 101306
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.117
  article-title: PPARs: key regulators of airway inflammation and potential therapeutic targets in asthma
  publication-title: Nucl Receptor Res
  doi: 10.11131/2018/101306
– volume: 56
  start-page: 219
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.2
  article-title: Understanding asthma phenotypes, endotypes, and mechanisms of disease
  publication-title: Clin Rev Allergy Immunol
  doi: 10.1007/s12016-018-8712-1
– ident: 2024101710515834000_7.2.00309-2020.44
  doi: 10.1165/rcmb.2017-0162OC
– ident: 2024101710515834000_7.2.00309-2020.87
  doi: 10.1164/rccm.200809-1512OC
– volume: 137
  start-page: 1433
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.43
  article-title: Asthma inflammatory phenotypes show differential microRNA expression in sputum
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2016.02.018
– ident: 2024101710515834000_7.2.00309-2020.59
  doi: 10.1016/S0014-2999(01)01321-8
– volume: 5
  start-page: 29
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.56
  article-title: From erythromycin to azithromycin and new potential ribosome-binding antimicrobials
  publication-title: Antibiotics
  doi: 10.3390/antibiotics5030029
– volume: 134
  start-page: 117
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.8
  article-title: A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2017.12.001
– volume: 193
  start-page: A6841
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.96
  article-title: A narrow spectrum kinase inhibitor, RV1729, induces bronchodilation of human small airways and rescues agonist-induced desensitization of the 2 adrenoreceptor (2AR)
  publication-title: Am J Respir Crit Care Med
– ident: 2024101710515834000_7.2.00309-2020.1
– ident: 2024101710515834000_7.2.00309-2020.69
  doi: 10.1183/09031936.00093913
– volume: 5
  start-page: 327
  year: 2010
  ident: 2024101710515834000_7.2.00309-2020.16
  article-title: Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD
  publication-title: Int J Chron Obstruct Pulmon Dis
– volume: 23
  start-page: 241
  year: 2009
  ident: 2024101710515834000_7.2.00309-2020.88
  article-title: Cytokine antagonists for the treatment of asthma: progress to date
  publication-title: BioDrugs
  doi: 10.2165/11317130-000000000-00000
– ident: 2024101710515834000_7.2.00309-2020.7
  doi: 10.1016/j.jaci.2013.03.044
– ident: 2024101710515834000_7.2.00309-2020.108
  doi: 10.1164/rccm.200601-072OC
– volume: 54
  start-page: 39
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.123
  article-title: Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: a systematic review and meta-analysis
  publication-title: Pulm Pharmacol Ther
  doi: 10.1016/j.pupt.2018.11.007
– volume: 4
  start-page: 797
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.82
  article-title: Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(16)30227-2
– ident: 2024101710515834000_7.2.00309-2020.97
  doi: 10.1152/ajplung.00233.2002
– ident: 2024101710515834000_7.2.00309-2020.103
  doi: 10.1183/13993003.01510-2018
– ident: 2024101710515834000_7.2.00309-2020.122
  doi: 10.1186/s12931-016-0436-2
– volume: 12
  start-page: 125
  year: 2020
  ident: 2024101710515834000_7.2.00309-2020.14
  article-title: Circulating microRNAs and T-cell cytokine expression are associated with the characteristics of asthma exacerbation
  publication-title: Allergy Asthma Immunol Res
  doi: 10.4168/aair.2020.12.1.125
– volume: 161
  start-page: 550
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.17
  article-title: Inflammatory pattern of the bronchial mucosa in patients with asthma with airway hyperresponsiveness to hypoosmotic stimulus
  publication-title: Bull Exp Biol Med
  doi: 10.1007/s10517-016-3458-3
– volume: 12
  start-page: 628
  year: 2015
  ident: 2024101710515834000_7.2.00309-2020.32
  article-title: Changing pattern of sputum cell counts during successive exacerbations of chronic obstructive pulmonary disease
  publication-title: COPD
– volume: 22
  start-page: 69
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.77
  article-title: Asthma and obesity: is weight reduction the key to achieve asthma control?
  publication-title: Curr Opin Pulm Med
  doi: 10.1097/MCP.0000000000000226
– ident: 2024101710515834000_7.2.00309-2020.90
  doi: 10.1016/j.rmed.2015.05.003
– ident: 2024101710515834000_7.2.00309-2020.50
  doi: 10.1056/NEJMoa0904006
– ident: 2024101710515834000_7.2.00309-2020.28
  doi: 10.1164/ajrccm.161.2.9903097
– ident: 2024101710515834000_7.2.00309-2020.23
  doi: 10.1371/journal.pone.0100645
– ident: 2024101710515834000_7.2.00309-2020.101
  doi: 10.4049/jimmunol.1301360
– volume: 48
  start-page: PA4086
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.107
  article-title: Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers
  publication-title: Eur Respir J
– ident: 2024101710515834000_7.2.00309-2020.42
  doi: 10.1016/j.jaci.2009.02.024
– ident: 2024101710515834000_7.2.00309-2020.38
  doi: 10.1378/chest.119.5.1329
– volume: 8
  start-page: 19
  year: 2015
  ident: 2024101710515834000_7.2.00309-2020.106
  article-title: Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential
  publication-title: J Recept Ligand Channel Res
– volume: 37
  start-page: 50
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.19
  article-title: Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma
  publication-title: Allergy Asthma Pro
  doi: 10.2500/aap.2016.37.3944
– ident: 2024101710515834000_7.2.00309-2020.120
– volume: 139
  start-page: 1411
  year: 2017
  ident: 2024101710515834000_7.2.00309-2020.41
  article-title: Biologics and biomarkers for asthma, urticaria, and nasal polyposis
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2017.03.006
– ident: 2024101710515834000_7.2.00309-2020.51
  doi: 10.1371/journal.pone.0010235
– ident: 2024101710515834000_7.2.00309-2020.105
– ident: 2024101710515834000_7.2.00309-2020.84
  doi: 10.1164/rccm.201212-2318OC
– volume: 12
  start-page: 83
  year: 2012
  ident: 2024101710515834000_7.2.00309-2020.46
  article-title: In young children, persistent wheezing is associated with bronchial bacterial infection: a retrospective analysis
  publication-title: BMC Pediatr
  doi: 10.1186/1471-2431-12-83
– ident: 2024101710515834000_7.2.00309-2020.58
  doi: 10.1111/bph.12187
– ident: 2024101710515834000_7.2.00309-2020.64
  doi: 10.1016/0002-9610(94)90069-8
– ident: 2024101710515834000_7.2.00309-2020.66
  doi: 10.1111/bph.12077
– ident: 2024101710515834000_7.2.00309-2020.65
  doi: 10.1136/gut.33.3.397
– ident: 2024101710515834000_7.2.00309-2020.20
  doi: 10.1056/NEJMra1301758
– volume: 60
  start-page: 56
  year: 2013
  ident: 2024101710515834000_7.2.00309-2020.113
  article-title: Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2013.02.001
– volume: 38
  start-page: 483
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.3
  article-title: Type 2 innate lymphoid cells: at the cross-roads in allergic asthma
  publication-title: Semin Immunopathol
  doi: 10.1007/s00281-016-0556-2
– ident: 2024101710515834000_7.2.00309-2020.45
  doi: 10.1183/13993003.00405-2015
– ident: 2024101710515834000_7.2.00309-2020.49
  doi: 10.1016/j.jaci.2010.03.027
– ident: 2024101710515834000_7.2.00309-2020.30
  doi: 10.1186/1471-2466-13-11
– volume: 2016
  start-page: 6470364
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.21
  article-title: Does IL-17 respond to the disordered lung microbiome and contribute to the neutrophilic phenotype in asthma?
  publication-title: Mediators Inflamm
  doi: 10.1155/2016/6470364
– ident: 2024101710515834000_7.2.00309-2020.71
  doi: 10.1164/rccm.200707-1134OC
– volume: 13
  start-page: 1009
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.91
  article-title: The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
  publication-title: Int J Chron Obstruct Pulmon Dis
  doi: 10.2147/COPD.S150576
– volume: 7
  start-page: 2624
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.6
  article-title: Exploring the utility of noninvasive type 2 inflammatory markers for prediction of severe asthma exacerbations in children and adolescents
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2019.04.043
– volume: 83
  start-page: 247
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.104
  article-title: Role of neutralizing anti-murine interleukin-17A monoclonal antibody on chronic ozone-induced airway inflammation in mice
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2016.06.041
– ident: 2024101710515834000_7.2.00309-2020.89
  doi: 10.1016/j.jaci.2014.07.039
– ident: 2024101710515834000_7.2.00309-2020.5
  doi: 10.1183/13993003.00588-2019
– volume: 11
  start-page: 14
  year: 2015
  ident: 2024101710515834000_7.2.00309-2020.116
  article-title: Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma
  publication-title: Allergy Asthma Clin Immunol
  doi: 10.1186/s13223-015-0081-1
– volume: 142
  start-page: 15
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.10
  article-title: Towards precision medicine in severe asthma: treatment algorithms based on treatable traits
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2018.07.006
– ident: 2024101710515834000_7.2.00309-2020.34
  doi: 10.1136/thx.2006.073429
– ident: 2024101710515834000_7.2.00309-2020.18
  doi: 10.1016/j.intimp.2014.08.009
– ident: 2024101710515834000_7.2.00309-2020.68
  doi: 10.1136/thoraxjnl-2014-206067
– ident: 2024101710515834000_7.2.00309-2020.98
  doi: 10.1371/journal.pone.0015781
– ident: 2024101710515834000_7.2.00309-2020.4
  doi: 10.1016/j.ccm.2012.06.008
– volume: 72
  start-page: 1761
  year: 2017
  ident: 2024101710515834000_7.2.00309-2020.37
  article-title: Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes
  publication-title: Allergy
  doi: 10.1111/all.13184
– ident: 2024101710515834000_7.2.00309-2020.22
  doi: 10.1136/thx.2006.061358
– volume: 121
  start-page: 631
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.12
  article-title: Is small airways dysfunction related to asthma control and type 2 inflammation?
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2018.08.009
– volume: 28
  start-page: 63
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.73
  article-title: What's new in the Global Initiative for Asthma 2018 report and beyond
  publication-title: Allergo J Int
  doi: 10.1007/s40629-018-0079-6
– ident: 2024101710515834000_7.2.00309-2020.55
  doi: 10.1111/j.1365-2222.2012.03979.x
– volume: 20
  start-page: 121
  year: 1994
  ident: 2024101710515834000_7.2.00309-2020.67
  article-title: Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man
  publication-title: Drugs Exp Clin Res
– volume: 150
  start-page: 694
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.74
  article-title: Advances in bronchial thermoplasty
  publication-title: Chest
  doi: 10.1016/j.chest.2016.03.012
– ident: 2024101710515834000_7.2.00309-2020.115
  doi: 10.1586/eci.10.66
– volume: 9
  start-page: 2037
  year: 2020
  ident: 2024101710515834000_7.2.00309-2020.15
  article-title: The role of airways 17β-estradiol as a biomarker of severity in postmenopausal asthma: a pilot study
  publication-title: J Clin Med Res
– volume: 79
  start-page: 756
  year: 2015
  ident: 2024101710515834000_7.2.00309-2020.119
  article-title: Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12536
– volume: 117
  start-page: 551
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.9
  article-title: Variability of blood eosinophil count as an asthma biomarker
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2016.08.010
– volume: 48
  start-page: PA4176
  year: 2016
  ident: 2024101710515834000_7.2.00309-2020.102
  article-title: Expression of nasal and bronchial IL-17F and related cytokines in frequent exacerbators with neutrophilic severe asthma
  publication-title: Eur Respir J
– ident: 2024101710515834000_7.2.00309-2020.83
  doi: 10.1186/1465-9921-14-137
– ident: 2024101710515834000_7.2.00309-2020.114
  doi: 10.1164/rccm.201609-1830OC
– ident: 2024101710515834000_7.2.00309-2020.27
  doi: 10.1136/thx.2009.124925
– ident: 2024101710515834000_7.2.00309-2020.53
  doi: 10.1016/j.jaci.2011.04.039
– ident: 2024101710515834000_7.2.00309-2020.57
  doi: 10.1183/09031936.00102014
– volume: 6
  start-page: 570
  year: 2018
  ident: 2024101710515834000_7.2.00309-2020.79
  article-title: Overweight, obesity, and lung function in children and adults – a meta-analysis
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2017.07.010
– volume: 7
  start-page: CD009339
  year: 2012
  ident: 2024101710515834000_7.2.00309-2020.78
  article-title: Weight loss interventions for chronic asthma
  publication-title: Cochrane Database Syst Rev
– ident: 2024101710515834000_7.2.00309-2020.99
  doi: 10.1136/thorax.57.7.590
– ident: 2024101710515834000_7.2.00309-2020.111
  doi: 10.1034/j.1398-9995.2000.00505.x
– volume: 380
  start-page: 2009
  year: 2019
  ident: 2024101710515834000_7.2.00309-2020.54
  article-title: Mometasone or tiotropium in mild asthma with a low sputum eosinophil level
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1814917
SSID ssj0001528466
Score 2.4403622
SecondaryResourceType review_article
Snippet Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 309
SubjectTerms Reviews
Title Identification and treatment of T2-low asthma in the era of biologics
URI https://www.ncbi.nlm.nih.gov/pubmed/34109244
https://www.proquest.com/docview/2539883715
https://pubmed.ncbi.nlm.nih.gov/PMC8181790
https://doaj.org/article/7daf183783d548cd86912cf933ea93bf
Volume 7
WOSCitedRecordID wos000684169700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2312-0541
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001528466
  issn: 2312-0541
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2312-0541
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001528466
  issn: 2312-0541
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB5RVFW9VH0T2iJX6pGUxE5i5wjVIg6AOFC0N8uvEStBFu0u5cZvZxxnV7tV1V56ycEPxZoZe77x4xuAbwEJJVhT5bV3Mq9MoCllfZ3XSNEGFxXankj76lSen6vxuL1YS_UV74QleuAkuAPpDZaR9Vx4AtfOq6YtuUOKw4NphcW4-hLqWQum0vtgWnabZqAZov4HhGM4wZPye5EOFYqY4XvNFfWM_X-Cmb_fllxzP8ev4dWAG9lhGu8b2ArdW3hxNpyMv4NRenGLwxYcM51nq0vkbIrskuc30wdm5ovrW8MmHSPkx8LMxLrExDRx8_fw83h0-eMkH1Ik5I68yiJHXxrhGyUxkKPmRcNRSlvV1lIcprC2tbfBNCGQK0aPonXO85LKpEfXUoD6Aba7aRd2gBXIsWhQcEmiQ9Mqr2RrIsCqhCHBZ8CX0tJu4A-PaSxudB9HKKGXIta9iHUUcQb7q053iT7j782PohpWTSP3dV9AFqEHi9D_sogMvi6VqGmuxAMQ04Xp_VzzWrSKepZ1Bh-TUle_Im9eUCxaZSA31L0xls2abnLd83ET5ok8Z7v_Y_Cf4CVBsiq9dvwM24vZffgCz92vxWQ-24Nncqz2elOn79nj6AkMfABm
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+treatment+of+T2-low+asthma+in+the+era+of+biologics&rft.jtitle=ERJ+open+research&rft.au=Kyriakopoulos%2C+Chris&rft.au=Gogali%2C+Athena&rft.au=Bartziokas%2C+Konstantinos&rft.au=Kostikas%2C+Konstantinos&rft.date=2021-04-01&rft.issn=2312-0541&rft.eissn=2312-0541&rft.volume=7&rft.issue=2&rft_id=info:doi/10.1183%2F23120541.00309-2020&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2312-0541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2312-0541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2312-0541&client=summon